JP6692676B2 - ネフロネクチンを含むう蝕治療剤 - Google Patents
ネフロネクチンを含むう蝕治療剤 Download PDFInfo
- Publication number
- JP6692676B2 JP6692676B2 JP2016079544A JP2016079544A JP6692676B2 JP 6692676 B2 JP6692676 B2 JP 6692676B2 JP 2016079544 A JP2016079544 A JP 2016079544A JP 2016079544 A JP2016079544 A JP 2016079544A JP 6692676 B2 JP6692676 B2 JP 6692676B2
- Authority
- JP
- Japan
- Prior art keywords
- nephronectin
- therapeutic agent
- caries
- dentin
- caries therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000006776 nephronectin Human genes 0.000 title claims description 37
- 108010086803 nephronectin Proteins 0.000 title claims description 37
- 208000002925 dental caries Diseases 0.000 title claims description 34
- 239000003814 drug Substances 0.000 title claims description 26
- 229940124597 therapeutic agent Drugs 0.000 title claims description 26
- 210000004268 dentin Anatomy 0.000 claims description 22
- 210000003074 dental pulp Anatomy 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 230000002308 calcification Effects 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 102100027935 Attractin-like protein 1 Human genes 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 6
- 239000000920 calcium hydroxide Substances 0.000 description 6
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004416 odontoblast Anatomy 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 101710105839 Dentin matrix acidic phosphoprotein 1 Proteins 0.000 description 2
- 102400001058 Dentin phosphoprotein Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 108010088492 dentin sialophosphoprotein Proteins 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000003566 sealing material Substances 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150080498 ALP gene Proteins 0.000 description 1
- 101150079550 BSP gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102100022375 Dentin matrix acidic phosphoprotein 1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101000995831 Mus musculus Nephronectin Proteins 0.000 description 1
- 102100031475 Osteocalcin Human genes 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 210000001968 dental pulp cell Anatomy 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000029795 kidney development Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 108010051904 phosphophoryn Proteins 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000246 tooth germ Anatomy 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
[1]ネフロネクチンを有効成分として含有するう蝕治療剤。
[2]象牙質の修復に用いられる[1]に記載のう蝕治療剤。
[3]虫歯および/または欠損歯の修復に用いられる[1]に記載のう蝕治療剤。
[4]虫歯および/または欠損歯の象牙質の修復に用いられる[1]に記載のう蝕治療剤。
[5]歯髄保存療法において用いられる[1]〜[4]のいずれかに記載のう蝕治療剤。
[6]薬学的に許容し得る担体および/またはキャリアーをさらに含有する[1]〜[5]のいずれかに記載のう蝕治療剤。
即ち、ネフロネクチン0.1〜10μg/mLで表面をコーティングしたポリスチレン製培養容器でMDPC-23細胞を培養したところ、何もコーティングしていない培養容器で培養したものと比べて、以下の結果が得られた。
・Dose依存的(特に10μg/mL)に細胞の増殖を促進した。
・細胞形態には変化は無かった。
・10μg/mLのコーティングで、細胞の増殖だけではなく細胞の分化も促進した(象牙質関連の諸遺伝子の発現、および石灰化の指標であるアルカリホスファターゼの発現が上昇した)。
・同時並行での実験は行っていないが、発明者が以前にDentin phosphophorynのRGDペプチドを用いて行った時の濃度と比較すると1/100程度の濃度で同等の効果が認められた。
本発明のう蝕治療剤は、好ましくは、虫歯および/または欠損歯の修復に用いられる。
さらに本発明の歯修復剤は、好ましくは、虫歯および/または欠損歯などの象牙質の修復に用いられる。
本発明のう蝕治療剤は、好ましくは、歯髄保存療法における象牙質の修復に用いられる。
実験材料
ネフロネクチン:市販品(R&D systems社)
実験方法の概要を図2に示す。
象牙芽細胞株(MDPC-23)を、10%ウシ胎児血清(FBS, Gibco, Canada)含有Dulbecco's modified eagle's medium (DMEM)を用いて37℃、5% CO2条件下で培養した。細胞の石灰化誘導のため、第5日目から、培地を50μg/mLアスコルビン酸,10mM β−グリセロリン酸含有DMEMに交換した。
MDPC-23の増殖は、Cell Counting Kit-8 (CCK-8,同仁化学)を用いて測定した。ネフロネクチンを16時間コーティングしたウェル(96 well plate, non-tissue culture polystyrene)の上にMDPC-23細胞を播種した(500/well, DMEM+5%FBS)。1、2、4、6日培養した。培養後、テトラゾリム塩であるWST-8を各ウェルに10μL添加し、1時間45分間培養後、細胞内脱水素酵素によってWST-8が還元されて生成する水溶性ホルマザンの450nmにおける吸光度を、マルチプレートリーダー(Bio-Rad, USA)で測定した。結果を図3に示す。
ネフロネクチンを16時間コーティングしたウェル(12 well plate, non-tissue culture polystyrene)の上にMDPC-23細胞を播種した(2.5×104/well, DMEM+5%FBS)(D0)。細胞形態(D2 & D3)の撮影は位相差顕微鏡を用いて行われた。結果を図4に示す。
ネフロネクチンを16時間コーティングしたウェル(12 well plate, non-tissue culture polystyrene)の上にMDPC-23細胞を播種した(2.5×104/well, DMEM+5%FBS)。培養して3日及び7日後に、LabAssay ALPキット(和光純薬)を用いてALP活性を測定した。なおALP活性は、Pierce BSA Protein Assayで測定した各ウェルの総蛋白質あたりの活性(Unit/μg protein)として算出した。結果を図5に示す。
ネフロネクチンを16時間コーティングしたウェル(12 well plate, non-tissue culture polystyrene)の上にMDPC-23細胞を播種した(2.5×104/well,DMEM+5%FBS)。7日及び9日間培養した細胞回収後、acid guanidinium-phenol-chloroform(AGPC)法によりtotal RNAの抽出を行った。RNA量を吸光光度計にて測定し、oligo(dT)プライマー(Invitrogen)を用いてcDNAを作製した。得られたcDNAより、Taq DNA polymerase (Invitrogen)と特異的プライマーを用いたPCR法により象牙質形成関連遺伝子であるBSP, ALP, OCN, OPN, DMP-1, Runx-2の発現を検討した。Internal controlとしては、β-actinを採用した。
ネフロネクチンを16時間コーティングしたウェル(12 well plate, non-tissue culture polystyrene)の上にMDPC-23細胞を播種した(2.5×104/well,DMEM+5%FBS)。細胞培養10日後、細胞を10% formalin neutral buffer solution(和光純薬)て、20分間固定後十分水洗した。1%アリザリンレッドS(pH4.1)染色液で10分間染色し(37℃)、蒸留水で3回洗浄後、digital imaging system(フナコシ)を用いて染色写真を撮影した。また、石灰化沈着物の定量は、10% cetylpyridinium chloride (CPC)による溶出液をマルチプレートリーダー(Bio-Rad, USA)にて波長570nmで測定し、optical densityで示した。結果は図9に示す。
実験結果のすべての数値は平均値±標準偏差で示した。また、得られたデータは、Tukey's multiple comparison testにより、有意水準5%における有意差検定を行った。
何もコーティングしていない培養容器で培養したものと比べて、以下の結果が得られた。
・Dose依存的(特に10μg/mL)に細胞の増殖を促進した。
・細胞形態には変化は無かった。
・10μg/mLのコーティングで、細胞の増殖だけではなく細胞の分化も促進した(象牙質関連の諸遺伝子の発現、および石灰化の指標であるアルカリホスファターゼの発現が上昇した)。
・同時並行での実験は行っていないが、発明者が以前にDentin phosphophorynのRGDペプチドを用いて行った時の濃度と比較すると1/100程度の濃度で同等の効果が認められた。
配列番号2、3:BSP遺伝子リアルタイムRT-PCR プライマ塩基配列
配列番号4、5:ALP遺伝子リアルタイムRT-PCR プライマ塩基配列
配列番号6、7:OCN遺伝子リアルタイムRT-PCR プライマ塩基配列
配列番号8、9:OPN遺伝子リアルタイムRT-PCR プライマ塩基配列
配列番号10、11:DMP-1遺伝子リアルタイムRT-PCR プライマ塩基配列
配列番号12、13:Runx-2遺伝子リアルタイムRT-PCR プライマ塩基配列
配列番号14、15:β-actin(Internal control) 遺伝子リアルタイムRT-PCR プライマ塩基配列
Claims (6)
- 配列番号1に記載のアミノ酸配列を含むネフロネクチンを有効成分として含有するう蝕治療剤。
- 歯の象牙質の修復に用いられる請求項1に記載のう蝕治療剤。
- 虫歯および/または欠損歯の修復に用いられる請求項1に記載のう蝕治療剤。
- 虫歯および/または欠損歯の象牙質の修復に用いられる請求項1に記載のう蝕治療剤。
- 歯髄保存療法において用いられる請求項1〜4のいずれかに記載のう蝕治療剤。
- 薬学的に許容し得る担体および/またはキャリアーをさらに含有する請求項1〜5のいずれかに記載のう蝕治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016079544A JP6692676B2 (ja) | 2016-04-12 | 2016-04-12 | ネフロネクチンを含むう蝕治療剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016079544A JP6692676B2 (ja) | 2016-04-12 | 2016-04-12 | ネフロネクチンを含むう蝕治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017190293A JP2017190293A (ja) | 2017-10-19 |
JP6692676B2 true JP6692676B2 (ja) | 2020-05-13 |
Family
ID=60084508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016079544A Active JP6692676B2 (ja) | 2016-04-12 | 2016-04-12 | ネフロネクチンを含むう蝕治療剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6692676B2 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6911425B2 (en) * | 2000-08-16 | 2005-06-28 | Acologix, Inc. | Integrin binding motif containing peptides and methods of treating skeletal diseases |
CA2417207C (en) * | 2000-08-16 | 2010-04-20 | Toshiyuki Yoneda | Dental products comprising bone growth enhancing peptide |
KR101013999B1 (ko) * | 2004-03-19 | 2011-02-14 | 재단법인서울대학교산학협력재단 | 표면에 골조직 형성 증진 펩타이드가 고정된 차폐막 및임플란트 |
JP5519121B2 (ja) * | 2008-06-02 | 2014-06-11 | 学校法人東日本学園 | 新規rgd含有ペプチドおよび象牙質再生剤、骨再生剤、歯周組織再生剤 |
-
2016
- 2016-04-12 JP JP2016079544A patent/JP6692676B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017190293A (ja) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Ion channel functional protein kinase TRPM7 regulates Mg ions to promote the osteoinduction of human osteoblast via PI3K pathway: In vitro simulation of the bone-repairing effect of Mg-based alloy implant | |
Gomes‐Cornélio et al. | Bioactivity of MTA Plus, Biodentine and an experimental calcium silicate‐based cement on human osteoblast‐like cells | |
Xu et al. | Copper-modified Ti6Al4V alloy fabricated by selective laser melting with pro-angiogenic and anti-inflammatory properties for potential guided bone regeneration applications | |
Song et al. | In vitro biocompatibility and bioactivity of calcium silicate‑based bioceramics in endodontics | |
Lyngstadaas et al. | Enamel matrix proteins; old molecules for new applications | |
Okiji et al. | Reparative dentinogenesis induced by mineral trioxide aggregate: a review from the biological and physicochemical points of view | |
Kukiattrakoon et al. | The effect of acidic agents on surface ion leaching and surface characteristics of dental porcelains | |
Miron et al. | The effect of enamel matrix proteins on the spreading, proliferation and differentiation of osteoblasts cultured on titanium surfaces | |
Eid et al. | In vitro osteogenic/dentinogenic potential of an experimental calcium aluminosilicate cement | |
Cipriano et al. | Degradation of bioresorbable Mg–4Zn–1Sr intramedullary pins and associated biological responses in vitro and in vivo | |
Sanz et al. | Cytocompatibility and bioactive potential of AH Plus Bioceramic Sealer: An in vitro study | |
Chen et al. | Endowing biodegradable Zinc implants with dual-function of antibacterial ability and osteogenic activity by micro-addition of Mg and Ag (≤ 0.1 wt.%) | |
An et al. | Promotive effect of zinc ions on the vitality, migration, and osteogenic differentiation of human dental pulp cells | |
Wu et al. | Sodium fluoride under dose range of 2.4–24 μM, a promising osteoimmunomodulatory agent for vascularized bone formation | |
Rubert et al. | Synthetic peptides analogue to enamel proteins promote osteogenic differentiation of MC3T3-E1 and mesenchymal stem cells | |
Camargo et al. | Incorporating N-acetylcysteine and tricalcium phosphate into epoxy resin-based sealer improved its biocompatibility and adhesiveness to radicular dentine | |
Yeom et al. | Platelet‐rich plasma enhances the differentiation of dental pulp progenitor cells into odontoblasts | |
Gu et al. | Osteogenic stimulation of human dental pulp stem cells with self‐setting biphasic calcium phosphate cement | |
Lee et al. | Effects of mineral trioxide aggregate mixed with hydration accelerators on osteoblastic differentiation | |
Spagnuolo et al. | Regeneration of dentin-pulp complex: Effect of calcium-based materials on hDPSCs differentiation and gene expression | |
Hengameh et al. | Effects of two bioactive materials on survival and osteoblastic differentiation of human mesenchymal stem cells | |
Zhao et al. | Injectable CNPs/DMP1-loaded self-assembly hydrogel regulating inflammation of dental pulp stem cells for dentin regeneration | |
JP6692676B2 (ja) | ネフロネクチンを含むう蝕治療剤 | |
Sollazzo et al. | Genetic effect of zirconium oxide coating on osteoblast‐like cells | |
Yu et al. | The osteogenesis performance of titanium modified via plasma-enhanced chemical vapor deposition: In vitro and in vivo studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200311 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200331 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200415 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6692676 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |